Loading...

About Us

We believe in a diverse range of personnel to bring creative skills, thoughts, and ideas to the table.
Philip J. Rosenfeld
Philip J. Rosenfeld, MD, PhD.
AMD SCIENTIFIC ADVISORY BOARD
Professor of Ophthalmology, Bascom Palmer Eye Institute, USA

Dr. Rosenfeld received both his MD and PhD degrees from the Johns Hopkins School of Medicine and he completed a research fellowship and residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Following his residency, Dr. Rosenfeld completed a Vitreoretinal fellowship at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. In 1996, he joined the faculty of the Bascom Palmer Eye Institute where he is now a Professor of Ophthalmology. Dr. Rosenfeld is a member of the American Academy of Ophthalmology (AAO), the American Society of Retinal Specialists (ASRS), the Retina Society, the Macula Society, and the Association for Research in Vision and Ophthalmology (ARVO).

Research/Clinical Interests
Dr. Rosenfeld specializes in medical and surgical diseases of the retina. Dr. Rosenfeld’s research interests focus on early-onset and late-onset maculopathies with a particular emphasis on age-related macular degeneration, the genetics of AMD, and therapies for both dry and wet AMD. Since joining the faculty at the Bascom Palmer Eye Institute, Dr. Rosenfeld has been a principal investigator in several of the photodynamic therapy trials using verteporfin, as well as the Macugen (pegaptanib, Eyetech) Phase II/III trials and the Lucentis (Genentech) Phase I/II/III trials. He also pioneered the use of intravitreal Avastin for the treatment of neovascular AMD and other exudative diseases of the retina. He is currently involved in additional clinical trials investigating other anti-angiogenic therapies for neovascular AMD. In addition, he has been involved in the development of spectral domain and swept source OCT imaging technologies, as well as OCT algorithms for use in characterizing AMD phenotypes, studying disease progression, and developing clinical trial endpoints.